Physician profile
Daniel Sullivan
NPI 1255317988
$1,482.11
in general payments reported to CMS, 2019-2025
30 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $121 · 2021: $51.44 · 2022: $220 · 2023: $40.60 · 2024: $64.80 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.11 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $275.31 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $119.89 | 2019-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $114.15 | 2025 | Voquezna |
| Amgen INC. | $106.66 | 2024-2025 | Tezspire, Tepezza |
| Genzyme Corporation | $83.94 | 2020-2023 | |
| Acclarent, INC | $75.27 | 2019-2022 | |
| Glaxosmithkline, LLC. | $70.80 | 2025 | Nucala |
| Bausch & Lomb Americas INC. | $57.02 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Ars Pharmaceuticals Operations, INC. | $53.69 | 2025 | Neffy |
| Stryker Corporation | $51.90 | 2022 | |
| Alcon Vision LLC | $50.20 | 2025 | Tryptyr, Eysuvis |
| Oyster Point Pharma, INC. | $44.12 | 2024-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $33.88 | 2025 | Photrexa Viscous and Photrexa |
| Abbvie INC. | $32.02 | 2024-2025 | |
| Ibsa Pharma INC. | $31.47 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $29.13 | 2022 | |
| Cochlear Americas | $26.42 | 2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Tolmar Pharmaceuticals, INC. | $23.22 | 2021 | |
| Dompe US, INC. | $21.37 | 2022 | |
| Tandem Diabetes Care, INC. | $21.35 | 2020 | |
| Intersect Ent, INC. | $19.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.90 | 2025 | Xhance |
| Optinose US, INC. | $17.68 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.57 | 2022 | |
| Abbott Laboratories | $16.35 | 2020 | |
| Pfizer INC. | $16.12 | 2025 | |
| Smith+Nephew, INC. | $16.08 | 2023 | Sinu-Foam |
| Aerin Medical INC. | $15.97 | 2022 | |
| Kaleo, INC. | $12.77 | 2021 | |
| Amarin Pharma, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.